P4HA2 Promotes Tumor Progression and is Transcriptionally Regulated by SP1 in Colorectal Cancer

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2024 Jun 10

PMID 38857058

Authors

Xuening Dang

Xiaojian Chen

Zhonglin Liang

Zhujiang Dai

Wenjun Ding

Jinglue Song

Jihong Fu

Affiliations

Soon will be listed here.

Abstract

P4HA2 has been implicated in various malignant tumors; however, its expression and functional role in colorectal cancer (CRC) remain poorly elucidated. This study aims to investigate the involvement of P4HA2 in CRC metastasis and progression, uncovering the underlying mechanisms. In colorectal cancer (CRC), P4HA2 exhibited overexpression, and elevated levels of P4HA2 expression were associated with an unfavorable prognosis. Functional assays demonstrated P4HA2's regulation of cell proliferation, and epithelial-mesenchymal transition (EMT) both in vitro and in vivo. Additionally, the AGO1 expression was correlated with P4HA2, and depletion of AGO1 reversed the proliferation and EMT function induced by P4HA2. Chromatin immunoprecipitation (ChIP) and luciferase assays suggested that the transcription factor SP1 binds to the promoter sequence of P4HA2, activating its expression in CRC. This study unveiled SP1 as a transcriptional regulator of P4HA2 in CRC and AGO1 is a probable target of P4HA2. In conclusion, P4HA2 emerges as a potential prognostic biomarker and promising therapeutic target in colorectal cancer.

Citing Articles

A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.

Mezentsev A, Durymanov M, Makarov V Curr Oncol. 2024; 31(9):4818-4854.

PMID: 39329988 PMC: 11431409. DOI: 10.3390/curroncol31090360.

References

Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui A . Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2015; 35(21):2789-800. DOI: 10.1038/onc.2015.342. View

Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y . Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine. 2019; 45:168-180. PMC: 6642319. DOI: 10.1016/j.ebiom.2019.06.048. View

Walker C, Mojares E, Del Rio Hernandez A . Role of Extracellular Matrix in Development and Cancer Progression. Int J Mol Sci. 2018; 19(10). PMC: 6213383. DOI: 10.3390/ijms19103028. View

Xiong G, Deng L, Zhu J, Rychahou P, Xu R . Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 2014; 14:1. PMC: 3880410. DOI: 10.1186/1471-2407-14-1. View

Bosse G, Simard M . A new twist in the microRNA pathway: Not Dicer but Argonaute is required for a microRNA production. Cell Res. 2010; 20(7):735-7. DOI: 10.1038/cr.2010.83. View

Elzamly S, Badri N, Padilla O, Dwivedi A, Alvarado L, Hamilton M . Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy. Breast Cancer (Auckl). 2018; 12:1178223418788074. PMC: 6071152. DOI: 10.1177/1178223418788074. View

Li Q, Wang Q, Zhang Q, Zhang J, Zhang J . Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer. Am J Transl Res. 2019; 11(11):6938-6951. PMC: 6895525. View

Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gaskell S . Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-72. DOI: 10.1126/science.1059796. View

Li L, Yu C, Gao H, Li Y . Argonaute proteins: potential biomarkers for human colon cancer. BMC Cancer. 2010; 10:38. PMC: 2843668. DOI: 10.1186/1471-2407-10-38. View

10.

Feng G, Li J, Yang Z, Zhang S, Liu Y, Zhang W . Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene. 2017; 36(50):6895-6905. DOI: 10.1038/onc.2017.291. View

11.

Toss M, Miligy I, Gorringe K, AlKawaz A, Khout H, Ellis I . Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). Br J Cancer. 2018; 119(12):1518-1526. PMC: 6288166. DOI: 10.1038/s41416-018-0337-x. View

12.

Luo R, Zhuo Y, Du Q, Xiao R . POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1. BMC Pulm Med. 2021; 21(1):117. PMC: 8034198. DOI: 10.1186/s12890-021-01476-9. View

13.

Ribatti D, Tamma R, Annese T . Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020; 13(6):100773. PMC: 7182759. DOI: 10.1016/j.tranon.2020.100773. View

14.

Xu W, Sheng Y, Guo Y, Huang Z, Huang Y, Wen D . Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019; 234(10):18466-18479. DOI: 10.1002/jcp.28483. View

15.

Agarwal S, Behring M, Kim H, Bajpai P, Chakravarthi B, Gupta N . Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. Transl Oncol. 2020; 13(4):100754. PMC: 7082635. DOI: 10.1016/j.tranon.2020.100754. View

16.

Qi H, Ongusaha P, Myllyharju J, Cheng D, Pakkanen O, Shi Y . Prolyl 4-hydroxylation regulates Argonaute 2 stability. Nature. 2008; 455(7211):421-4. PMC: 2661850. DOI: 10.1038/nature07186. View

17.

Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L . High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol. 2015; 24(3):220-5. DOI: 10.1016/j.suronc.2015.05.004. View

18.

Cao Y, Han Q, Li J, Jia Y, Zhang R, Shi H . P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition. J Cancer. 2020; 11(10):2788-2799. PMC: 7086251. DOI: 10.7150/jca.38401. View

19.

Wu C, So J, Davis-Dusenbery B, Qi H, Bloch D, Shi Y . Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol Cell Biol. 2011; 31(23):4760-74. PMC: 3232924. DOI: 10.1128/MCB.05776-11. View

20.

Beishline K, Azizkhan-Clifford J . Sp1 and the 'hallmarks of cancer'. FEBS J. 2014; 282(2):224-58. DOI: 10.1111/febs.13148. View